Members of the Board of Directors, management and external investors have undertaken to exercise warrants of approximately SEK 4.3 million, corresponding to 32.9 percent of outstanding warrants of series TO7
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.
Prolight Diagnostics AB (publ) (“Prolight” or the “Company”) hereby announces that the Company has obtained subscription commitment agreements for the exercise of warrants of series TO7 from members of the Board and management in the Company, as well as external investors, amounting to approximately SEK 4.3 million, corresponding to approximately 32.9 percent of the total amount of outstanding warrants of series TO7. Prior to the exercise of warrants of series TO7, the Board of Directors and management's insider ownership in the Company amounts to approximately 25 percent of the outstanding shares. The exercise period for the warrants of series TO7 is currently ongoing and will continue up until October 18, 2024.
The Board and management in the Company, as well as external investors, intend to exercise 35,782,128 warrants of series TO7, corresponding to a total of approximately SEK 4.3 million. Entered subscription commitments cover approximately 32.9 percent of all outstanding warrants of series TO7. If all the warrants of series TO7 are exercised, the Company will receive approximately SEK 13.1 million before issuing costs.
“We are very pleased with the great interest already shown, both internally and externally, to join and support the company as we enter an exciting period filled with significant milestones. We hope that as many of our warrant holders of series TO7 as possible will also participate, so that we can accelerate our efforts”, says Ulf Bladin, CEO of Prolight Diagnostics.
Summarized terms for the warrants of series TO7:
Exercise period: October 7, 2024 – October 18, 2024.
Exercise price: SEK 0.12 per share.
Issue size: 108,756,747 warrants of series TO7 entitling to subscription of 108,756,747 shares. If all the warrants are exercised the Company will receive approximately SEK 13.1 million before issuing costs.
Last day for trading with warrants of series TO7: October 15, 2024.
Note that the warrants that are not exercised at latest on October 18, 2024, or sold at the latest on October 15, 2024, will expire without value. For the warrants not to lose their value, the holder must actively exercise the warrants for subscription of new shares or sell the warrants. Please observe that certain nominees might close their application earlier than October 18, 2024.
Shares, share capital, and dilution
If all warrants of series TO7 are exercised the total number of shares in the Company will increase by 108,756,747, from 597,287,105 shares to 706,043,852 shares, and the share capital will increase with SEK 10,875,674.70, from SEK 59,728,710.50 to SEK 70,604,385.20. This corresponds to a maximum dilution of approximately 15.4 percent of the total number of shares and 15.4 percent of the total number of votes in the Company. The dilution effect has been calculated as the number of additional shares and votes, respectively, in relation to the number of existing and additional shares and votes, respectively.
How the warrants are exercised:
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscription will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
The application form including instructions for payment will be available at the Company’s website, www.prolightdx.com.
Advisors
Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the exercise of the warrants of series TO7.